1-9 of 9
Thomas E. Delea, MSIA
Close
Sort by
Journal Articles

Real-World Effectiveness of Voxelotor for Treating Sickle Cell Disease in the US

Ahmar Urooj Zaidi, MD, Thokozeni Lipato, MD, Ofelia A. Alvarez, MD, Alexander Lonshteyn, PhD, Derek Weycker, PhD, Nhat Pham, Thomas E Delea, MSIA, Irene Agodoa, MD, Ze Cong, PhD, Nirmish Shah, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 25.
https://doi.org/10.1182/blood-2020-140525
Published: 2020
Journal Articles

The Impact of Hemoglobin Level on Risk of End-Organ Damage among Patients with Sickle Cell Disease - A Large-Scale, Longitudinal Analysis

William B Ershler, MD, Laura M De Castro, MD MHSc, Zahra Pakbaz, MD, Aaron Moynahan, Derek Weycker, PhD, Nhat Pham, Thomas E Delea, MSIA, Irene Agodoa, MD, Ze Cong, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 27–28.
https://doi.org/10.1182/blood-2020-140572
Published: 2020
Journal Articles

Healthcare Utilization (HRU) and Costs Among Multiple Myeloma (MM) Patients (Pts) Receiving Second or Subsequent Line Treatment (Tx) with Carfilzomib (CAR) or Pomalidomide (POM)

Sumeet Panjabi, PhD, May Hagiwara, PhD, Thomas E. Delea, MSIA
Journal: Blood
Blood (2016) 128 (22): 2419.
https://doi.org/10.1182/blood.V128.22.2419.2419
Published: 2016
Journal Articles

Patterns of Medication Use in Patients with Relapsed and/or Refractory Multiple Myeloma

May Hagiwara, PhD, Aaron Moynahan, MA, Ze Cong, Yaozhu J. Chen, MPA, Emilie Duchesneau, BA, Dana Hurley, PharmD, MS, Thomas E. Delea, MSIA
Journal: Blood
Blood (2015) 126 (23): 4497.
https://doi.org/10.1182/blood.V126.23.4497.4497
Published: 2015
Journal Articles

Costs and Consequences of Inadequate Compliance with Deferoxamine Therapy in Patients with Transfusion-Dependent Thalassemia.

Thomas E. Delea, MSIA, Oleg Sofrygin, MS, Jean-Francois Baladi, MBA, Simu K. Thomas, PhD, Pradyumna D. Phatak, MD, Thomas D. Coates, MD
Journal: Blood
Blood (2005) 106 (11): 3134.
https://doi.org/10.1182/blood.V106.11.3134.3134
Published: 2005
Journal Articles

Cost-Effectiveness of Once-Daily Oral Chelation Therapy with Deferasirox (Exjade®, ICL670) Versus Infusional Deferoxamine in Transfusion-Dependent Thalassemic Patients.

Thomas E. Delea, MSIA, Oleg Sofrygin, MS, Simu K. Thomas, PhD, Jean-Francois Baladi, MBA, Pradyumna D. Phatak, MD, Thomas D. Coates, MD
Journal: Blood
Blood (2005) 106 (11): 1341.
https://doi.org/10.1182/blood.V106.11.1341.1341
Published: 2005
Journal Articles

Utilization and Costs of Deferoxamine in Patients with Thalassemia, Sickle-Cell Disease, or Myelodysplastic Syndrome Receiving Frequent Transfusions.

Thomas E. Delea, MSIA, May Hagiwara, PhD, Simu K. Thomas, PhD, Jean-Francois Baladi, MBA, Pradyumna D. Phatak, MD, Thomas D. Coates, MD
Journal: Blood
Blood (2005) 106 (11): 5583.
https://doi.org/10.1182/blood.V106.11.5583.5583
Published: 2005
Journal Articles

Once-Daily Oral Deferasirox (Exjade®, ICL670) Versus Infusional Deferoxamine as Iron Chelation Therapy in Patients with Sickle-Cell Disease Receiving Frequent Transfusions: A Cost-Effectiveness Analysis.

Thomas E. Delea, MSIA, Simu K. Thomas, PhD, Jean-Francois Baladi, MBA, Thomas D. Coates, MD
Journal: Blood
Blood (2005) 106 (11): 5584.
https://doi.org/10.1182/blood.V106.11.5584.5584
Published: 2005
Journal Articles

Cost-Effectiveness Analysis of Oral Iron Chelation Therapy with Deferasirox (Exjade®, ICL670) Versus Infusional Chelation Therapy with Deferoxamine in Patients with Transfusion-Dependent Myelodysplastic Syndrome.

Thomas E. Delea, MSIA, Simu K. Thomas, PhD, Jean-Francois Baladi, MBA, Pradyumna D. Phatak, MD
Journal: Blood
Blood (2005) 106 (11): 5585.
https://doi.org/10.1182/blood.V106.11.5585.5585
Published: 2005